Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension

Heart

Volumn 83, Issue 4, 2000, Pages 406-409

  Ziesche, R ^a   Petkov, V ^a   Wittmann, K ^a   Kopatschka, J ^a   Stiebellehner, L ^a   Schenk, P ^a   Block, L H ^a   Germann, P ^a   Roder G ^a   Ullrich, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Epoprostenol; Primary pulmonary hypertension; Vascular reactivity

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART INDEX; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0034123998     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.83.4.406     Document Type: Article

References (17)

1. Rubin LJ, Rich S, eds. Pathophysiology of primary pulmonary hypertension. From physiology to molecular mechanisms. In: Primary pulmonary hypertension. New York: Marcel Dekker, 1997:83-130.
2. Wagenvoort C, Wagenvoort N. Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970;42:1163-84.
3. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-30.
4. Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatr Clin North Am 1999;46:331-45.
5. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
6. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension study group. N Engl J Med 1996; 334:296-302.
7. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
8. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
9. Higenbottam TW, Butt AZ, McMahon A, et al. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
10. Zhao YJ, Wang J, Rubin LJ, et al. Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery. Am J Physiol 1997;272:H904-12.
11. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197-208.
12. Rich S, ed. Primary pulmonary hypertension. Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, September 1998:17.
13. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;i:1046-7.
14. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
15. Alli AI, Barette WE, Cunnane S, et al. Prostaglandin I2 (prostacyclin) inhibits intracellular calcium release [abstract]. J Physiol (Lond) 1978;276:P40-1.
16. + channel opening. Prog Clin Biol Res 1990;327:299-306.
17. Hoehn T, Krause M, Hentschel R. High-frequency ventilation augments the effect of inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Eur Respir J 1998;11:234-8.